20 reports of this reaction
0.9% of all AVOBENZONE, OCTISALATE, AND OCTOCRYLENE reports
#17 most reported adverse reaction
RASH MACULAR is the #17 most commonly reported adverse reaction for AVOBENZONE, OCTISALATE, AND OCTOCRYLENE, manufactured by Alchemee, LLC. There are 20 FDA adverse event reports linking AVOBENZONE, OCTISALATE, AND OCTOCRYLENE to RASH MACULAR. This represents approximately 0.9% of all 2,163 adverse event reports for this drug.
Patients taking AVOBENZONE, OCTISALATE, AND OCTOCRYLENE who experience rash macular should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH MACULAR is a less commonly reported adverse event for AVOBENZONE, OCTISALATE, AND OCTOCRYLENE, but still significant enough to appear in the safety profile.
In addition to rash macular, the following adverse reactions have been reported for AVOBENZONE, OCTISALATE, AND OCTOCRYLENE:
The following drugs have also been linked to rash macular in FDA adverse event reports:
RASH MACULAR has been reported as an adverse event in 20 FDA reports for AVOBENZONE, OCTISALATE, AND OCTOCRYLENE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH MACULAR accounts for approximately 0.9% of all adverse event reports for AVOBENZONE, OCTISALATE, AND OCTOCRYLENE, making it a notable side effect.
If you experience rash macular while taking AVOBENZONE, OCTISALATE, AND OCTOCRYLENE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.